{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T09:06:53Z","timestamp":1774775213647,"version":"3.50.1"},"reference-count":53,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","license":[{"start":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T00:00:00Z","timestamp":1727136000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:sec>\n            <jats:title>Background.<\/jats:title>\n            <jats:p>Chronic graft-versus-host disease (cGVHD) is a cause of late morbidity and nonrelapse mortality (NRM) after allogenic hematopoietic stem cell transplantation (allo-HSCT). Although studies evaluating haploidentical allo-HSCT (haplo-HSCT) using posttransplant cyclophosphamide (PTCy) demonstrate lower cGVHD rates, comprehensive data describing the clinical profile, risk factors, or outcomes of cGVHD within this platform are scarce.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods.<\/jats:title>\n            <jats:p>We conducted a retrospective multicenter analysis of 389 consecutive patients who underwent haplo-HSCT PTCy in 7 transplant centers of the Spanish Group Grupo Espa\u00f1ol de Trasplante Hematopoy\u00e9tico y Terapia Celular (GETH-TC) between 2008 and 2020 describing incidence, clinical profile, risk factors, and cGVHD outcomes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results.<\/jats:title>\n            <jats:p>Ninety-five patients of 389 developed cGVHD. Our data revealed that the incidence and severity of cGVHD are lower than those reported for HLA-identical transplantation with conventional prophylaxis and that the strongest predictor for cGVHD was previous acute GVHD (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u20050.031). Also, recipient age \u226560 y (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u20050.044) was protective against cGVHD. Moreover, patients with moderate cGVHD had longer event-free survival at 3 y than other patients (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u20050.016) and a lower relapse rate at 3 y (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u20050.036).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions.<\/jats:title>\n            <jats:p>Our results support the fact that the incidence and severity of cGVHD are lower than those reported for HLA-identical transplantation with conventional prophylaxis. In this series, patients who develop moderate cGVHD after haplo-HSCT PTCy had a higher overall survival and event-free survival, and lower relapse, suggesting higher graft-versus-leukemia effect. Although this is the largest series focused on characterizing cGVHD in haplo-HSCT PTCy, further prospective studies are needed to confirm the findings.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/tp.0000000000005034","type":"journal-article","created":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T04:00:49Z","timestamp":1714449649000},"page":"2134-2143","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Characterization of Chronic Graft-versus-host Disease After Haploidentical Stem Cell Transplantation With Posttransplant Cyclophosphamide: A Study on Behalf of GETH-TC"],"prefix":"10.1097","volume":"108","author":[{"given":"Marta","family":"Fonseca-Santos","sequence":"first","affiliation":[{"name":"Hematology Department, Hospital Universitario de Salamanca, IBSAL, CIBERONC, Centro de Investigaci\u00f3n del C\u00e1ncer-IBMCC (USAL-CSIC), Salamanca, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebeca","family":"Bailen","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Madrid, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oriana","family":"Lopez-Godino","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Universitario Morales Meseguer, Murcia, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatriz","family":"Herruzo-Delgado","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Universitario Regional de M\u00e1laga, M\u00e1laga, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Aranzazu","family":"Bermudez","sequence":"additional","affiliation":[{"name":"Servicio de Hematologia y Hemoterapia, Hospital Universitario Marqu\u00e9s de Valdecilla, Santander, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Garc\u00eda-Cadenas","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital de la Santa Creu I Sant Pau, Barcelona, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Huguet-Mas","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Germans Trias i Pujol, Barcelona, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christelle","family":"Ferra-Coll","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Germans Trias i Pujol, Barcelona, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert","family":"Esquirol","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital de la Santa Creu I Sant Pau, Barcelona, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Cort\u00e9s-Rodriguez","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Universitario de Salamanca, IBSAL, CIBERONC, Centro de Investigaci\u00f3n del C\u00e1ncer-IBMCC (USAL-CSIC), Salamanca, Spain."},{"name":"Statistical Department, Universidad de Salamanca, Salamanca, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucrecia","family":"Ya\u00f1ez-Sansegundo","sequence":"additional","affiliation":[{"name":"Servicio de Hematologia y Hemoterapia, Hospital Universitario Marqu\u00e9s de Valdecilla, Santander, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Jesus","family":"Pascual-Cascon","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Universitario Regional de M\u00e1laga, M\u00e1laga, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inmaculada","family":"Heras","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Universitario Morales Meseguer, Murcia, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mi","family":"Kwon","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Madrid, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc\u00eda","family":"Lopez-Corral","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Universitario de Salamanca, IBSAL, CIBERONC, Centro de Investigaci\u00f3n del C\u00e1ncer-IBMCC (USAL-CSIC), Salamanca, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of Grupo Espa\u00f1ol de Trasplante Hematopoy\u00e9tico y Terapia Celular","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,9,24]]},"reference":[{"key":"R1-20250604","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S0140-6736(83)91793-2","article-title":"Mismatched family donors for bone-marrow transplantation as treatment for acute leukaemia.","volume":"321","author":"Powles","year":"1983","journal-title":"Lancet"},{"key":"R2-20250604","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1056\/NEJM198509263131301","article-title":"Marrow transplantation from related donors other than HLA-identical siblings.","volume":"313","author":"Beatty","year":"1985","journal-title":"N Engl J Med"},{"key":"R3-20250604","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1200\/JCO.2005.09.117","article-title":"Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse.","volume":"23","author":"Aversa","year":"2005","journal-title":"J Clin Oncol"},{"key":"R4-20250604","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide.","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"R5-20250604","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1056\/NEJM198901263200401","article-title":"Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma.","volume":"320","author":"Anasetti","year":"1989","journal-title":"N Engl J Med"},{"key":"R6-20250604","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1182\/blood-2003-02-0430","article-title":"Allogeneic hematopoietic stem cell transplantation from family members other than HLA-identical siblings over the last decade (1991-2000).","volume":"102","author":"Kanda","year":"2003","journal-title":"Blood"},{"key":"R8-20250604","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1038\/s41409-019-0465-9","article-title":"The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies.","volume":"54","author":"Passweg","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"R9-20250604","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s12185-019-02660-8","article-title":"HLA-haploidentical stem cell transplantation using posttransplant cyclophosphamide.","volume":"110","author":"Sugita","year":"2019","journal-title":"Int J Hematol"},{"key":"R10-20250604","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1038\/bmt.2015.93","article-title":"Unmanipulated haploidentical bone marrow transplantation and post-transplant cyclophosphamide for hematologic malignanices following a myeloablative conditioning: an update.","volume":"50","author":"Bacigalupo","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"R11-20250604","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1053\/j.seminhematol.2016.01.005","article-title":"Haploidentical bone marrow and stem cell transplantation: experience with post-transplantation cyclophosphamide.","volume":"53","author":"Robinson","year":"2016","journal-title":"Semin Hematol"},{"key":"R12-20250604","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1200\/JCO.2017.73.7775","article-title":"Haploidentical hematopoietic cell transplantation using post-transplantation cyclophosphamide: does graft source matter?.","volume":"35","author":"Devine","year":"2017","journal-title":"J Clin Oncol"},{"key":"R13-20250604","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1001\/jamaoncol.2019.3541","article-title":"Haploidentical stem cell transplantation with posttransplant cyclophosphamide therapy vs other donor transplantations in adults with hematologic cancers: a systematic review and meta-analysis.","volume":"5","author":"Gagelmann","year":"2019","journal-title":"JAMA Oncol"},{"key":"R14-20250604","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s00277-021-04399-x","article-title":"Post-transplant cyclophosphamide versus antithymocyte globulin in allogeneic hematopoietic cell transplantation: a meta-analysis.","volume":"100","author":"Gao","year":"2021","journal-title":"Ann Hematol"},{"key":"R15-20250604","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1182\/blood.2019001323","article-title":"How we perform haploidentical stem cell transplantation with posttransplant cyclophosphamide.","volume":"134","author":"McCurdy","year":"2019","journal-title":"Blood"},{"key":"R16-20250604","doi-asserted-by":"crossref","first-page":"204.e1","DOI":"10.1016\/j.jtct.2022.01.020","article-title":"Post-transplantation cyclophosphamide after HLA identical compared to haploidentical donor transplant in acute myeloid leukemia: a study on behalf of GETH-TC.","volume":"28","author":"Bail\u00e9n","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"R17-20250604","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1053\/bbmt.2003.50026","article-title":"Chronic graft-versus-host disease.","volume":"9","author":"Lee","year":"2003","journal-title":"Biol Blood Marrow Transplant"},{"key":"R18-20250604","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.bbmt.2014.10.021","article-title":"Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the center for international blood and marrow transplant research.","volume":"21","author":"Arai","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"R19-20250604","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/s41409-022-01875-4","article-title":"Impact of chronic graft-versus-host-disease on intensive care outcome in allogeneic hematopoietic stem cell recipients.","volume":"58","author":"Lueck","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"R20-20250604","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1016\/j.bbmt.2012.06.014","article-title":"Graft-versus-host disease induced graft-versus-leukemia effect: greater impact on relapse and disease-free survival after reduced intensity conditioning.","volume":"18","author":"Weisdorf","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"R21-20250604","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1182\/blood-2015-04-639831","article-title":"Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia.","volume":"126","author":"Ciurea","year":"2015","journal-title":"Blood"},{"key":"R22-20250604","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.bbmt.2017.01.068","article-title":"T cell\u2013replete peripheral blood haploidentical hematopoietic cell transplantation with post-transplantation cyclophosphamide results in outcomes similar to transplantation from traditionally matched donors in active disease acute myeloid leukemia.","volume":"23","author":"How","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"R23-20250604","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1053\/bbmt.2002.v8.pm12171484","article-title":"Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide.","volume":"8","author":"O\u2019Donnell","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"R24-20250604","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/j.bbmt.2016.05.010","article-title":"Comparison of outcomes after peripheral blood haploidentical versus matched unrelated donor allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia: a retrospective single-center review.","volume":"22","author":"Rashidi","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"R25-20250604","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1182\/blood-2010-08-302109","article-title":"Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria.","volume":"117","author":"Flowers","year":"2011","journal-title":"Blood"},{"key":"R26-20250604","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.bbmt.2016.12.633","article-title":"Ex vivo CD34 + \u2013selected T cell\u2013depleted peripheral blood stem cell grafts for allogeneic hematopoietic stem cell transplantation in acute leukemia and myelodysplastic syndrome is associated with low incidence of acute and chronic graft-versus-host disease and high treatment response.","volume":"23","author":"Barba","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"R27-20250604","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1089\/scd.2018.0259","article-title":"Clinical features of chronic graft-versus-host disease following haploidentical transplantation combined with infusion of a cord blood.","volume":"28","author":"Tao","year":"2019","journal-title":"Stem Cells Dev"},{"key":"R28-20250604","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1016\/j.bbmt.2020.07.035","article-title":"Differences in graft-versus-host disease characteristics between haploidentical transplantation using post-transplantation cyclophosphamide and matched unrelated donor transplantation using calcineurin inhibitors.","volume":"26","author":"Solh","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"R29-20250604","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1182\/bloodadvances.2020003654","article-title":"Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors.","volume":"5","author":"Grunwald","year":"2021","journal-title":"Blood Adv"},{"key":"R30-20250604","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.bbmt.2019.10.019","article-title":"Disability related to chronic graft-versus-host disease.","volume":"26","author":"Hamilton","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"R31-20250604","doi-asserted-by":"crossref","first-page":"835","DOI":"10.3324\/haematol.2018.202754","article-title":"Disability related to chronic graft-versus-host disease after alternative donor hematopoietic cell transplantation.","volume":"104","author":"Fatobene","year":"2019","journal-title":"Haematologica"},{"key":"R32-20250604","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.bbmt.2012.08.014","article-title":"Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning.","volume":"19","author":"Raiola","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"R33-20250604","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","article-title":"International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium.","volume":"22","author":"Harris","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"R34-20250604","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and staging working group report.","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"R35-20250604","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report.","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"R36-20250604","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.bbmt.2015.02.025","article-title":"Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 response criteria working group report.","volume":"21","author":"Lee","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"R37-20250604","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1016\/j.bbmt.2012.06.019","article-title":"Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: results of a prospective phase II trial.","volume":"18","author":"Solomon","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"R38-20250604","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.bbmt.2014.05.029","article-title":"Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts.","volume":"20","author":"Raiola","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"R39-20250604","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.bbmt.2015.10.018","article-title":"Late acute and chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation.","volume":"22","author":"Arora","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"R40-20250604","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/leu.2014.336","article-title":"A survey on unmanipulated haploidentical hematopoietic stem cell transplantation in adults with acute leukemia.","volume":"29","author":"Piemontese","year":"2015","journal-title":"Leukemia"},{"key":"R41-20250604","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1200\/JCO.2017.72.8428","article-title":"Mobilized peripheral blood stem cells versus unstimulated bone marrow as a graft source for T-cell\u2013replete haploidentical donor transplantation using post-transplant cyclophosphamide.","volume":"35","author":"Bashey","year":"2017","journal-title":"JCO"},{"key":"R42-20250604","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/j.bbmt.2020.05.001","article-title":"Risk factors for graft-versus-host disease in haploidentical hematopoietic cell transplantation using post-transplant cyclophosphamide.","volume":"26","author":"Im","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"R43-20250604","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41409-023-02134-w","article-title":"Peripheral blood haploidentical hematopoietic cell transplantation for patients aged 70 years and over with acute myeloid leukemia or high-risk myelodysplastic syndrome.","volume":"59","author":"Harbi","year":"2024","journal-title":"Bone Marrow Transplant"},{"key":"R44-20250604","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/bjh.13923","article-title":"Low incidence of chronic GVHD after HLA \u2010haploidentical peripheral blood stem cell transplantation with post\u2010transplantation cyclophosphamide in older patients.","volume":"176","author":"Devillier","year":"2017","journal-title":"Br J Haematol"},{"key":"R45-20250604","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1200\/JCO.2014.60.4777","article-title":"Outcomes of nonmyeloablative HLA-haploidentical blood or marrow transplantation with high-dose post-transplantation cyclophosphamide in older adults.","volume":"33","author":"Kasamon","year":"2015","journal-title":"JCO"},{"key":"R46-20250604","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/S0140-6736(09)60237-3","article-title":"Graft-versus-host disease.","volume":"373","author":"Ferrara","year":"2009","journal-title":"Lancet"},{"key":"R47-20250604","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1182\/blood-2015-01-623991","article-title":"Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide.","volume":"125","author":"McCurdy","year":"2015","journal-title":"Blood"},{"key":"R48-20250604","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.bbmt.2017.11.030","article-title":"T cell-replete haploidentical transplantation with post-transplantation cyclophosphamide for Hodgkin lymphoma relapsed after autologous transplantation: reduced incidence of relapse and of chronic graft-versus-host disease compared with HLA-identical related donors.","volume":"24","author":"Mariotti","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"R49-20250604","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1182\/blood.2019000487","article-title":"Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation.","volume":"134","author":"Battipaglia","year":"2019","journal-title":"Blood"},{"key":"R50-20250604","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0171-2985(96)80033-7","article-title":"Cyclophosphamide-induced immunological tolerance: an overview.","volume":"195","author":"Mayumi","year":"1996","journal-title":"Immunobiology"},{"key":"R51-20250604","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1038\/s41409-021-01389-5","article-title":"Steroid-refractory chronic graft-versus-host disease: treatment options and patient management.","volume":"56","author":"Wolff","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"R52-20250604","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jtct.2022.07.013","article-title":"Characteristics of graft-versus-host disease (GvHD) after post-transplantation cyclophosphamide versus conventional GvHD prophylaxis.","volume":"28","author":"Saliba","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"R53-20250604","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s12185-021-03228-1","article-title":"A phase II study of post-transplant cyclophosphamide combined with tacrolimus for GVHD prophylaxis after HLA-matched related\/unrelated allogeneic hematopoietic stem cell transplantation.","volume":"115","author":"Nakamae","year":"2022","journal-title":"Int J Hematol"},{"key":"R54-20250604","doi-asserted-by":"crossref","first-page":"451","DOI":"10.3324\/haematol.2011.055186","article-title":"Overlap subtype of chronic graft-versus-host disease is associated with an adverse prognosis, functional impairment, and inferior patient-reported outcomes: a chronic graft-versus-host disease consortium study.","volume":"97","author":"Pidala","year":"2012","journal-title":"Haematologica"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000005034","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T18:01:17Z","timestamp":1749060077000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000005034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,24]]},"references-count":53,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000005034","relation":{},"ISSN":["0041-1337","1534-6080"],"issn-type":[{"value":"0041-1337","type":"print"},{"value":"1534-6080","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,24]]}}}